{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-080348","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2023-07-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.190784+00:00","generated_at":"2026-06-13T09:18:46.483397+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cryoport expects Q2 revenue down 11% YoY; slashes FY2023 guidance to $233M-$243M","bullets":["Preliminary Q2 revenue $56.5M-$57.5M, down ~11% YoY; weak capital equipment demand.","FY2023 revenue guidance revised to $233M-$243M due to slower client ramps and trial delays.","Q2 impact from weaker global demand for capital equipment and clinical trial start delays.","CEO expects challenging conditions to persist into Q3 and Q4 2023.","Long-term outlook remains robust as cell and gene therapy industry CAGR expected >22%."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-080348","json":"https://secwatch.observer/filing/0001104659-23-080348.json","markdown":"https://secwatch.observer/filing/0001104659-23-080348.md","text":"https://secwatch.observer/filing/0001104659-23-080348.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465923080348/0001104659-23-080348-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465923080348/tm2321174d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T09:18:46.483397+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1c5b09a2a9ca2070567670a102638ba6a4850a7a","claim":"Cryoport, Inc. reported the second quarter ended June 30, 2023 results: revenue $56.5 to $57.5 million.","evidence_excerpt":"Second quarter 2023 total revenue is expected to be in the range of $56.5 to $57.5 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124524/000110465923080348/0001104659-23-080348-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$56.5 to $57.5 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"504f973fb439c1eadbd33ecd9df0b56fb9765ad4","claim":"Cryoport, Inc. reported full year 2023 results: revenue $233 to $243 million. Guidance lowered.","evidence_excerpt":"Based on current information, the Company is revising its full year financial outlook, with revenue now expected to be in the range of $233 to $243 million for 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124524/000110465923080348/0001104659-23-080348-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$233 to $243 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}